{"nctId":"NCT01584648","briefTitle":"A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma","startDateStruct":{"date":"2012-05-04","type":"ACTUAL"},"conditions":["Melanoma"],"count":423,"armGroups":[{"label":"Dabrafenib + Trametinib","type":"EXPERIMENTAL","interventionNames":["Drug: Dabrafenib","Drug: Trametinib"]},{"label":"Dabrafenib + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dabrafenib","Drug: Trametinib placebo"]}],"interventions":[{"name":"Dabrafenib","otherNames":["GSK2118436"]},{"name":"Trametinib","otherNames":["GSK1120212"]},{"name":"Trametinib placebo","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.\n* The subject must have a radiologically measurable tumor\n* The subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).\n* Able to swallow and retain oral medication\n* Sexually active subjects must use acceptable methods of contraception during the course of the study\n* Adequate organ system function and blood counts\n\nExclusion Criteria:\n\n* Prior treatment with a BRAF or a MEK inhibitor\n* Prior systemic anti-cancer treatment for Stage IIIC (unresectable) or Stage IV (metastatic) melanoma. Prior systemic treatment in the adjuvant setting is allowed. (Note: Ipilimumab treatment must end at least 8 weeks prior to randomization.)\n* The subject has received major surgery or certain tyes of cancer therapy with 21 days of starting treatment\n* Current use of prohibited medication listed in the protocol\n* Left ventricular ejection fraction less than the lower limit of normal\n* Uncontrolled blood pressurl\n* History or current evidence of retinal vein occlusion or central serous retinopathy\n* Brain metastases unless previously treated with surgery or stereotactic radiosurgery and the disease has been stable for at least 12 weeks\n* The subject is pregnant or nursing","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS) as Assessed by the Investigator","description":"PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started. In addition, the sum must have an absolute increase from nadir of 5 mm. The appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation, was also included as PD. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not have documented progression or death, PFS was censored at the date of the last adequate assessment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the interval of time between the date of randomization and the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) as Assessed by the Investigator","description":"ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR). A participant was defined as a responder if he/she sustained a complete response (CR: the disappearance of all target lesions and any pathological lymph nodes must have a short axis of \\<10 mm and the disappearance of all non-target lesions) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters or the persistence of 1 or more non-target lesions or lymph nodes identified as a site of disease at Baseline with a short axis of ≥10mm). Only descriptive analysis performed.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"Duration of response is defined as the time from the first documented complete response (CR: the disappearance of all target lesions and any pathological lymph nodes must have a short axis of \\<10 mm and the disappearance of all non-target lesions) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters or the persistence of 1 or more non-target lesions or lymph nodes identified as a site of disease at Baseline with a short axis of ≥10mm) until disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5mm or the appearance of one or more new lesions, or the worsening of non target lesions significant enough to require study treatment discontinuation. PD was based on the radiological evidence by investigator. Only descriptive analysis performed.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Trametinib Pharmacokinetic Concentrations","description":"Blood samples were collected for Pharmacokinetic (PK) analysis in all participants. Three blood samples were collected at Week 8: pre-dose, 1-3 hours post dose, and 4-6 hours post dose. One pre-dose blood sample was obtained at Weeks 16 and 24. Only descriptive analysis performed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9209","spread":"3.86587"},{"groupId":"OG001","value":"0.0000","spread":"0.00000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0382","spread":"6.86542"},{"groupId":"OG001","value":"0.0261","spread":"0.34598"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7496","spread":"5.64363"},{"groupId":"OG001","value":"0.0000","spread":"0.00000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0385","spread":"4.79185"},{"groupId":"OG001","value":"0.0039","spread":"0.03548"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5167","spread":"5.19171"},{"groupId":"OG001","value":"0.0548","spread":"0.62447"}]}]}]},{"type":"SECONDARY","title":"Dabrafenib and Dabrafenib Metabolites (Hydroxy-, Carboxy- and Desmethyl-Dabrafenib) Concentrations","description":"Blood samples were collected for PK analysis in all participants. Three blood samples were collected at Week 8: pre-dose, 1-3 hours post dose, and 4-6 hours post dose. One pre-dose blood sample was obtained at Weeks 16 and 24. Plasma concentrations of Dabrafenib (GSK2118436) and its metabolites (Hydroxy-Dabrafenib (GSK2285403), Carboxy-Dabrafenib (GSK2298683), and Desmethyl-Dabrafenib (GSK2167542)) were determined using the currently approved analytical methodology. Only descriptive analysis performed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":"204.85"},{"groupId":"OG001","value":"64.4","spread":"96.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1309.6","spread":"982.25"},{"groupId":"OG001","value":"1362.3","spread":"992.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"458.9","spread":"318.59"},{"groupId":"OG001","value":"539.7","spread":"553.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151.6","spread":"261.31"},{"groupId":"OG001","value":"151.02","spread":"381.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167.0","spread":"346.97"},{"groupId":"OG001","value":"156.5","spread":"357.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"346.6","spread":"261.73"},{"groupId":"OG001","value":"308.9","spread":"224.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"361.7","spread":"245.92"},{"groupId":"OG001","value":"341.8","spread":"240.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"316.9","spread":"208.51"},{"groupId":"OG001","value":"328.1","spread":"234.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"335.0","spread":"228.26"},{"groupId":"OG001","value":"331.0","spread":"250.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"306.2","spread":"203.77"},{"groupId":"OG001","value":"312.8","spread":"250.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":"123.93"},{"groupId":"OG001","value":"76.7","spread":"109.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"648.5","spread":"459.01"},{"groupId":"OG001","value":"672.7","spread":"519.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391.3","spread":"206.70"},{"groupId":"OG001","value":"502.2","spread":"356.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128.7","spread":"174.26"},{"groupId":"OG001","value":"121.1","spread":"195.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126.1","spread":"219.82"},{"groupId":"OG001","value":"145.7","spread":"265.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3237.2","spread":"1694.66"},{"groupId":"OG001","value":"3469.4","spread":"1854.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4286.3","spread":"2514.50"},{"groupId":"OG001","value":"4456.6","spread":"2687.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6238.3","spread":"2716.05"},{"groupId":"OG001","value":"6891.6","spread":"2739.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3842.4","spread":"2428.74"},{"groupId":"OG001","value":"4114.1","spread":"2432.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3617.9","spread":"2645.51"},{"groupId":"OG001","value":"4193.2","spread":"2730.78"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events and Serious Adverse Events","description":"Analysis of absolute and relative frequencies for Adverse Event (AE) and Serious Adverse Event (SAE) by primary System Organ Class (SOC) to characterize the safety of dabrafenib and trametinib combination therapy through the monitoring of relevant clinical and laboratory safety parameters. In addition, new malignancies and AEs possibly related to study treatment were collected even if they occurred more than 30 days post-treatment. Only descriptive analysis performed.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"205","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"Pre-treatment deaths were collected from screening visit up to the first day of treatment, for a maximum duration of 28 days. Patients who died during the screening period are considered as screen failure.\n\nOn treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 77.4 months (treatment duration ranged from 0.1 to 76.4 months).\n\nDeaths post treatment survival follow up were collected after the on- treatment period, up to approximately 6 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":100,"n":209},"commonTop":["Pyrexia","Fatigue","Nausea","Headache","Arthralgia"]}}}